

Japan Hematologic Malignancies Testing Market By Component (Kits and Services), By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

<https://marketpublishers.com/r/JAE88572CFF3EN.html>

Date: July 2024

Pages: 82

Price: US\$ 3,500.00 (Single User License)

ID: JAE88572CFF3EN

Abstracts

Japan Hematologic Malignancies Testing Market was valued at USD 129.18 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 13.18% through 2030. The Japan Hematologic Malignancies Testing market is driven by several key factors, including advancements in diagnostic technologies, increasing prevalence of hematologic cancers, and growing awareness of early detection and personalized medicine. Technological innovations such as next-generation sequencing (NGS) and digital PCR have significantly enhanced the accuracy, speed, and comprehensiveness of hematologic malignancy diagnostics. The rising incidence of blood cancers such as leukemia, lymphoma, and myeloma necessitates advanced testing solutions to improve patient outcomes. A strong emphasis on early detection and personalized treatment plans aligns with Japan's broader healthcare initiatives, fostering a demand for sophisticated diagnostic tests. Government support and investments in healthcare infrastructure also play a crucial role, ensuring accessibility

and adoption of cutting-edge diagnostic tools. Overall, these factors collectively drive the robust growth and development of the hematologic malignancies testing market in Japan.

Key Market Drivers

Technological Advancements in Diagnostic Methods

The Japan Hematologic Malignancies Testing Market is significantly driven by advancements in diagnostic technologies, which have revolutionized the detection and monitoring of hematologic cancers. Next-generation sequencing (NGS), digital PCR, and flow cytometry are at the forefront of these innovations. NGS offers the ability to analyze multiple genes simultaneously, providing comprehensive insights into genetic mutations associated with various blood cancers. This technology not only enhances the accuracy of diagnoses but also enables the identification of specific mutations that can guide targeted therapies. Digital PCR, known for its high sensitivity, allows for the detection of minimal residual disease, which is crucial for monitoring treatment response and early relapse detection. Flow cytometry, with its ability to analyze multiple parameters of individual cells, provides detailed information on the characteristics and progression of hematologic malignancies. In November 2019, Toshiba Corporation introduced an innovative cancer detection technology using microRNA (Note 1) in blood, employing a novel electrochemical microRNA detection method. At the research and development stage, the technology has demonstrated the ability to accurately differentiate between healthy individuals and patients with 13 types of cancer, within two hours with a 99% accuracy rate.

The integration of artificial intelligence (AI) and machine learning into these diagnostic tools is improving the interpretation of complex data, leading to more precise and personalized treatment plans. These advancements collectively enhance early diagnosis, treatment effectiveness, and overall patient outcomes in the hematologic malignancies testing market in Japan.

Increasing Prevalence of Hematologic Cancers

The rising incidence of hematologic malignancies, including leukemia, lymphoma, and myeloma, is a major driver for the Japan Hematologic Malignancies Testing Market. Over the past few decades, Japan has seen a steady increase in these blood cancers, necessitating the adoption of advanced diagnostic tools to manage and treat patients effectively. This increase is partly due to the country's aging population, as Japan has

one of the highest proportions of elderly individuals globally, and older individuals are more susceptible to these diseases. Improved diagnostic capabilities have led to better detection and reporting. The growing prevalence of these malignancies drives the demand for comprehensive testing solutions that can facilitate early detection and improve patient outcomes. Advanced diagnostic tools, such as next-generation sequencing (NGS) and digital PCR, are essential for identifying specific genetic mutations and minimal residual disease, thereby enabling personalized treatment plans and monitoring treatment responses. This trend underscores the critical need for continued innovation and investment in hematologic malignancies testing to address the increasing healthcare burden.

Government Support and Healthcare Policies

Government support and favorable healthcare policies are crucial drivers of the hematologic malignancies testing market in Japan. The proactive stance of the Japanese government in promoting cancer research and improving healthcare infrastructure significantly impacts the market. One of the key legislative frameworks is the Cancer Control Act, which underscores the government's commitment to reducing the cancer burden through comprehensive measures that include prevention, early detection, treatment, and palliative care. This act facilitates a coordinated approach to cancer management, ensuring that resources are allocated effectively to areas where they are most needed.

In addition to the Cancer Control Act, various funding programs for medical research play a pivotal role in advancing diagnostic technologies. Government agencies such as the Japan Agency for Medical Research and Development (AMED) provide substantial grants and financial support to research institutions and healthcare providers. These funds are instrumental in fostering innovation and development of new diagnostic tests, which are crucial for the early detection and accurate diagnosis of hematologic malignancies. By supporting cutting-edge research, the government ensures that the latest scientific advancements are translated into practical applications that benefit patients.

Growing Awareness and Early Detection Programs

Increased awareness about the importance of early detection and diagnosis of hematologic malignancies is significantly driving market growth. Public health campaigns and educational programs have been instrumental in emphasizing the critical role of early diagnosis in enhancing treatment outcomes and survival rates for

patients. These initiatives have successfully educated the public and healthcare professionals alike about the benefits of timely screenings and diagnostic tests. As a result of these efforts, there has been a noticeable rise in the number of individuals proactively seeking regular screenings and diagnostic evaluations. This trend is particularly evident in populations at higher risk of hematologic cancers, such as older adults and individuals with genetic predispositions. The growing demand for advanced testing solutions, including molecular diagnostics and imaging technologies, underscores the importance placed on early detection in clinical practice.

Governmental and non-governmental organizations have played a crucial role in supporting early detection programs through funding, advocacy, and collaboration with healthcare providers. By promoting early detection strategies and facilitating access to screening services, these organizations contribute significantly to improving patient outcomes and reducing the burden of hematologic malignancies on healthcare systems. The concerted efforts of public health campaigns, educational initiatives, and supportive policies have fostered a proactive approach to hematologic cancer management. The increasing awareness and implementation of early detection practices are expected to continue driving market expansion, facilitating earlier interventions, and ultimately improving the overall prognosis for individuals affected by hematologic malignancies.

Key Market Challenges

High Costs of Advanced Diagnostic Tests

One of the primary challenges in the Japan Hematologic Malignancies Testing Market is the high cost associated with advanced diagnostic tests. Technologies such as next-generation sequencing (NGS), digital PCR, and flow cytometry require significant investment in equipment, reagents, and skilled personnel. These costs can be prohibitive for smaller healthcare facilities and patients without comprehensive insurance coverage. Despite government support and subsidies, the financial burden remains a barrier to widespread adoption. The high cost of these tests can lead to disparities in access to advanced diagnostic tools, particularly in rural or underfunded areas. This challenge necessitates ongoing efforts to reduce costs through technological innovation, economies of scale, and strategic partnerships.

Limited Awareness and Understanding Among Patients and Clinicians

Another challenge is the limited awareness and understanding of advanced diagnostic tests among patients and clinicians. While there is increasing awareness about

hematologic malignancies, many patients and even some healthcare providers are not fully informed about the latest diagnostic technologies and their benefits. This lack of knowledge can result in underutilization of advanced testing methods, delaying diagnosis and appropriate treatment. Education and training programs are essential to bridge this knowledge gap, ensuring that both patients and clinicians are aware of the available diagnostic options and their potential impact on patient outcomes. Improving awareness can also foster a more proactive approach to early detection and personalized treatment strategies.

Key Market Trends

Increasing Investments in Healthcare Infrastructure

Significant investments in healthcare infrastructure are driving the hematologic malignancies testing market in Japan. Both public and private sectors are investing heavily in modernizing hospitals, diagnostic laboratories, and research facilities. These investments enhance the capacity and capabilities of healthcare institutions to conduct advanced diagnostic tests and provide comprehensive care for patients with hematologic malignancies. Improved infrastructure also ensures wider accessibility to cutting-edge diagnostic technologies, contributing to market growth. In March 2024, Nippon Shinyaku and Eli Lilly Japan K.K. have formed a strategic alliance in Japan for pirtobrutinib, a drug under development by Eli Lilly Japan for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Under this alliance agreement, Eli Lilly Japan will oversee the manufacturing and marketing approval processes for pirtobrutinib. Once approved, Eli Lilly Japan will supply the drug, while Nippon Shinyaku will take charge of distribution, sales, and information provision activities. The collaboration signifies a significant expansion of treatment options in the haematologic oncology field, leveraging Nippon Shinyaku's existing portfolio of haematological cancer drugs. The addition of pirtobrutinib is expected to enhance therapeutic choices for patients with MCL and CLL. By partnering with Nippon Shinyaku, which brings extensive experience in haematological cancers, Eli Lilly Japan aims to ensure the appropriate use of pirtobrutinib. This collaboration will facilitate the dissemination of accurate information to healthcare professionals, addressing the unmet medical needs of patients with MCL and CLL effectively.

Expansion of Clinical Trials and Research Activities

The expansion of clinical trials and research activities is another important driver of the hematologic malignancies testing market. Japan is increasingly becoming a hub for

clinical research due to its robust healthcare system, high-quality data, and regulatory support. Clinical trials are essential for evaluating the efficacy and safety of new diagnostic tests and treatments. They provide valuable insights into disease mechanisms and help in the development of innovative diagnostic solutions. The growing number of clinical trials and research initiatives in Japan is thus significantly contributing to the advancement of the hematologic malignancies testing market.

Segmental Insights

Component Insights

Based on the Component, diagnostic kits are currently more dominant than services. This dominance is driven by several factors, including their wide availability and ease of use. Kits for detecting genetic mutations or markers associated with leukemia, lymphoma, and myeloma are readily accessible and can be used in various healthcare settings, from large urban hospitals to smaller regional clinics. These kits offer standardized protocols, ensuring consistent and reliable results across different laboratories. Technological advancements have significantly enhanced the capabilities of diagnostic kits, incorporating innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), allowing for high-throughput and precise detection of genetic anomalies. The integration of these advanced technologies into diagnostic kits provides comprehensive data, crucial for the early and accurate diagnosis of hematologic cancers. This widespread accessibility and technological sophistication make diagnostic kits the preferred choice, facilitating early and effective treatment, and driving their dominance in the Japan Hematologic Malignancies Testing Market.

Technique Insights

Based on Technique, Next-Generation Sequencing (NGS) has emerged as the dominant technology, reshaping the landscape of molecular diagnostics for conditions like leukemia, lymphoma, and myeloma. NGS represents a significant advancement over traditional methods due to its ability to sequence large volumes of genetic data rapidly and accurately. This technology allows for the simultaneous analysis of multiple genes and genetic variations, providing comprehensive insights into the genomic profile of cancer cells.

The versatility of NGS makes it particularly suited for detecting specific mutations and genomic rearrangements that are critical for diagnosing hematologic malignancies and

guiding personalized treatment strategies. For instance, identifying mutations in genes such as FLT3 in acute myeloid leukemia (AML) or detecting chromosomal translocations like t(14;18) in follicular lymphoma can influence treatment decisions, enabling oncologists to tailor therapies based on individual genetic profiles. The sensitivity of NGS enables the detection of minimal residual disease (MRD), which is essential for monitoring treatment response and predicting relapse in hematologic cancers. By providing early and precise information about disease progression, NGS facilitates timely adjustments in treatment plans, improving patient outcomes and survival rates.

Regional Insights

In the Japan Hematologic Malignancies Testing Market, the Kanto region emerges as a dominant force due to its robust healthcare infrastructure, technological advancements, and demographic characteristics. Comprising Tokyo and its surrounding prefectures, Kanto hosts a dense network of leading medical institutions, research facilities, and university hospitals renowned for their expertise in oncology and hematology. These institutions are equipped with state-of-the-art diagnostic technologies such as Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and immunohistochemistry (IHC), enabling them to provide advanced diagnostic services for hematologic malignancies.

The region's prominence is bolstered by its large population base, including a significant proportion of elderly individuals who are at higher risk for hematologic cancers. This demographic profile underscores the critical need for accurate and timely diagnostic testing to facilitate early detection and personalized treatment strategies. Healthcare providers in Kanto leverage these advanced technologies not only for diagnosis but also for monitoring disease progression and treatment response, enhancing patient outcomes.

Key Market Players

Abbott Japan Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

Toshiba Corporation

Chugai Pharmaceutical Co., Ltd.

Illumina KK

Shimadzu Corp.

Guardant Health Japan Corp.

Chugai Pharmaceutical Co., Ltd.

Toray Industries, Inc.

Fujirebio Diagnostics Japan, Inc.

Report Scope:

In this report, the Japan Hematologic Malignancies Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Japan Hematologic Malignancies Testing Market, By Component:

Kits

Services

Japan Hematologic Malignancies Testing Market, By Technique:

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Fluorescence In-Situ Hybridization (FISH)

Immunohistochemistry (IHC)

Others

Japan Hematologic Malignancies Testing Market, By Therapeutic Indication:

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Others

Japan Hematologic Malignancies Testing Market, By End User:

Hospitals & Clinics

Diagnostic Laboratories

Academic & Research Institutions

Others

Japan Hematologic Malignancies Testing Market, By Region:

Hokkaido

Tohoku

Kanto

Chubu

Kansai

Chugoku

Shikoku

Kyushu

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Japan Hematologic Malignancies Testing Market.

Available Customizations:

Japan Hematologic Malignancies Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Component (Kits and Services)
 - 5.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)

- 5.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
- 5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map

6. HOKKAIDO HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Component
 - 6.2.2. By Technique
 - 6.2.3. By Therapeutic Indication
 - 6.2.4. By End User

7. TOHOKU HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Component
 - 7.2.2. By Technique
 - 7.2.3. By Therapeutic Indication
 - 7.2.4. By End User

8. KANTO HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Component
 - 8.2.2. By Technique
 - 8.2.3. By Therapeutic Indication
 - 8.2.4. By End User

9. CHUBU HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Component

9.2.2. By Technique

9.2.3. By Therapeutic Indication

9.2.4. By End User

10. KANSAI HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Component

10.2.2. By Technique

10.2.3. By Therapeutic Indication

10.2.4. By End User

11. CHUGOKU HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Component

11.2.2. By Technique

11.2.3. By Therapeutic Indication

11.2.4. By End User

12. SHIKOKU HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

12.1. Market Size & Forecast

12.1.1. By Value

12.2. Market Share & Forecast

12.2.1. By Component

12.2.2. By Technique

12.2.3. By Therapeutic Indication

12.2.4. By End User

13. KYUSHU HEMATOLOGIC MALIGNANCIES TESTING MARKET OUTLOOK

13.1. Market Size & Forecast

13.1.1. By Value

13.2. Market Share & Forecast

13.2.1. By Component

13.2.2. By Technique

13.2.3. By Therapeutic Indication

13.2.4. By End User

14. MARKET DYNAMICS

14.1. Drivers

14.2. Challenges

15. MARKET TRENDS & DEVELOPMENTS

15.1. Merger & Acquisition (If Any)

15.2. Product Launches (If Any)

15.3. Recent Developments

16. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET: SWOT ANALYSIS

17. PORTER'S FIVE FORCES ANALYSIS

17.1. Competition in the Industry

17.2. Potential of New Entrants

17.3. Power of Suppliers

17.4. Power of Customers

17.5. Threat of Substitute Products

18. COMPETITIVE LANDSCAPE

18.1. Abbott Japan Co., Ltd.

18.1.1. Business Overview

18.1.2. Company Snapshot

18.1.3. Products & Services

18.1.4. Financials (As Reported)

18.1.5. Recent Developments

18.1.6. Key Personnel Details

18.1.7. SWOT Analysis

18.2. Otsuka Pharmaceutical Co., Ltd.

18.3. Toshiba Corporation

18.4. Chugai Pharmaceutical Co., Ltd.

18.5. Illumina KK

18.6. Shimadzu Corp.

18.7. Guardant Health Japan Corp.

18.8. Chugai Pharmaceutical Co., Ltd.

18.9. Toray Industries, Inc.

18.10. Fujirebio Diagnostics Japan, Inc.

19. STRATEGIC RECOMMENDATIONS

20. ABOUT US & DISCLAIMER

I would like to order

Product name: Japan Hematologic Malignancies Testing Market By Component (Kits and Services), By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Product link: <https://marketpublishers.com/r/JAE88572CFF3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JAE88572CFF3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970